These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 9377495)
1. Skeletal Complications of Malignancy. Proceedings of a symposium. Bethesda, Maryland, April 19-20, 1997. Cancer; 1997 Oct; 80(8 Suppl):1527-701. PubMed ID: 9377495 [No Abstract] [Full Text] [Related]
2. Study of bisphosphonates leads to new views of bone remodeling, therapy for skeletal malignancy. Marwick C JAMA; 1997 Sep; 278(10):803-4. PubMed ID: 9293975 [No Abstract] [Full Text] [Related]
3. Abstracts of the 3rd North American Symposium on Skeletal Complications of Malignancy. April 2002, Bethesda, Maryland, USA. Oncology (Williston Park); 2003 Apr; 17(4 Suppl 3):9-54. PubMed ID: 12757009 [No Abstract] [Full Text] [Related]
4. Third North American Symposium on Skeletal Complications of Malignancy: summary of the scientific sessions. Mohla S; Weilbacher KN; Cher ML; Oyajobi BO; Poznak CV; Clohisy DR Cancer; 2003 Feb; 97(3 Suppl):719-25. PubMed ID: 12548568 [TBL] [Abstract][Full Text] [Related]
5. Hypercalcemia and bone resorption in malignancy. Walls J; Bundred N; Howell A Clin Orthop Relat Res; 1995 Mar; (312):51-63. PubMed ID: 7634618 [TBL] [Abstract][Full Text] [Related]
6. Role of parathyroid hormone-related peptide in hypercalcemia of malignancy and the development of osteolytic metastases. de Vernejoul MC Rev Rhum Engl Ed; 1997 Jun; 64(6 Suppl):119S-123S. PubMed ID: 9273953 [No Abstract] [Full Text] [Related]
8. [Biphosphonates in oncology]. Khosravi Shahi P; Díaz Muñoz de la Espada V An Med Interna; 2005 Nov; 22(11):544-7. PubMed ID: 16454591 [TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates in breast cancer patients with skeletal metastases. Shapiro CL Hematol Oncol Clin North Am; 1994 Feb; 8(1):153-63. PubMed ID: 8150777 [TBL] [Abstract][Full Text] [Related]
10. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy. Guay DR Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795 [TBL] [Abstract][Full Text] [Related]
11. Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy. Coleman RE Oncology (Williston Park); 1991 Aug; 5(8):55-60; discussion 60-2, 65. PubMed ID: 1834153 [TBL] [Abstract][Full Text] [Related]
12. [Bisphosphonates in the therapy of cancer patients]. Jantunen E; Kumpulainen E Duodecim; 1999; 115(1):27-32. PubMed ID: 11830857 [No Abstract] [Full Text] [Related]
13. The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia. Neville-Webbe Hl; Coleman RE Palliat Med; 2003 Sep; 17(6):539-53. PubMed ID: 14526888 [TBL] [Abstract][Full Text] [Related]
14. The antitumor potential of bisphosphonates. Clézardin P Semin Oncol; 2002 Dec; 29(6 Suppl 21):33-42. PubMed ID: 12584693 [TBL] [Abstract][Full Text] [Related]
15. Implications of bisphosphonate use for the dentist: an introduction. Kurtzman GM; Silverstein LH; Peden J; Shatz PC Dent Today; 2006 Jun; 25(6):80, 82-5; quiz 85. PubMed ID: 16792113 [No Abstract] [Full Text] [Related]
16. Use of bisphosphonates in patients with metastatic bone disease. Berenson JR; Lipton A Oncology (Williston Park); 1998 Nov; 12(11):1573-9; discussion 1579-81. PubMed ID: 9834935 [TBL] [Abstract][Full Text] [Related]
18. [The application advances of bisphosphonates in bone metastasis]. Liang P Zhongguo Gu Shang; 2008 Jun; 21(6):480-2. PubMed ID: 19108448 [TBL] [Abstract][Full Text] [Related]
19. Progress in the treatment and palliation of advanced breast cancer. Symposium proceedings. Jerusalem, 1993. Ann Oncol; 1994; 5 Suppl 7():S1-55. PubMed ID: 7532990 [No Abstract] [Full Text] [Related]
20. Bisphosphonates: expanded roles in the treatment of patients with cancer. Viale PH; Sanchez Yamamoto D Clin J Oncol Nurs; 2003; 7(4):393-401. PubMed ID: 12929272 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]